Topic 14

cancer tumor tumors biology cells therapy therapeutic cancers patients treatment cell patient survival breast metastasis microenvironment metastatic progression growth resistance lines clinical proliferation expression therapies inhibitors inhibition immune aggressive targeting anti immunotherapy vivo prognosis signaling chemotherapy inhibitor carcinoma drug oncogenic malignant melanoma target poor adenocarcinoma targeted checkpoint pathway derived response vitro tumorigenesis glioblastoma xenograft invasion lung associated mesenchymal suppressor kinase pancreatic activation efficacy resistant xenografts primary heterogeneity tumour models epithelial prostate promotes potential targets solid mutations phenotype combination migration ductal drugs subtypes apoptosis blockade relapse recurrence grade colorectal stromal upregulation driver prognostic receptor treated metastases cytotoxic mechanistically novel glioma ovarian

1216 items. Top items listed below.

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers 126 14 10 3

PD-L1 lncRNA splice promotes lung adenocarcinoma progression via enhancing c-Myc activity 108 14 10 3

Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer 98 14 10 3

P4HA2 is associated with prognosis, promotes proliferation, invasion, migration and EMT in glioma 98 14 3

Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance 126 14 10 3

Stroma transcriptomic and proteomic profile of prostate cancer metastasis xenograft models reveals conservation of bonemicroenvironment signatures 152 14 9 3

Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy 152 14 9 3

Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts 126 14 10 9

HDAC and MAPK/ERK inhibitors cooperate to reduce viability and stemness phenotype in medulloblastoma 186 108 14 10 3

Obesity-driven changes in ECM composition promote local invasion and metastasis of breast tumors 14 10 3

Divergent resistance mechanisms to immunotherapy explains response in different skin cancers. 173 14 10 3

RIPK2 Stabilizes c-Myc and is an Actionable Target for Inhibiting Prostate Cancer Metastasis 108 14 10 3

Abl kinase deficiency promotes AKT pathway activation and prostate cancer progression and metastasis 108 14 10 3

ATM Inhibition Synergizes with Fenofibrate in High Grade Serous Ovarian Cancer Cells 126 14 10 9 3

Patient-derived glioblastoma cells (GBM) exhibit distinct biomechanical profiles associated with altered activity in the cytoskeleton regulatory pathway 152 14 9 3

A novel role for the tumor suppressor gene ITF2 in lung tumorigenesis and chemotherapy response 186 14 9 3

Integrated genomics and comprehensive validation reveal novel drivers of genomic evolution in esophageal adenocarcinoma 14 9 3

Global computational alignment of tumor and cell line transcriptional profiles 43 14 9 4

ISL2 is an epigenetically silenced tumor suppressor and regulator of metabolism in pancreatic cancer 108 14 3

UBR-Box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target 108 14 3

Inhibition of the av integrin-TGF-b axis improves natural killer cell function against glioblastoma stem cells 152 14 10 3

Relationship Between Neuroendocrine and Immune Gene Expression in Small Cell Lung Cancer 14 9 3

Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model 126 14 10 9 3

UHRF1 drives the poor prognosis associated with RB loss in osteosarcoma 108 14 3

The Primary Tumor Immune Microenviornment Status Predicts the Response to Immunotherapy and Overall Survival in Breast Cancer 14 10 9

Aging interacts with tumor biology to produce major changes in the immune tumor microenvironment 14 9 3

IL-4 receptor targeting as an effective immunotherapy against triple-negative breast cancer 126 14 10 3

Nuclear Transport Factor 2 (NTF2) suppresses metastatic melanoma by modifying cell migration, metastasis, and gene expression 108 14 3

ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells 108 14 3

Identification of Wee1 as Target in Combination with Avapritinib for the Treatment of Gastrointestinal Stromal Tumors 152 126 14 10 3

A multi-layered systems approach for renal cell carcinoma 14 9

Tumor-specific EphA2 receptor tyrosine kinase inhibits anti-tumor immunity by recruiting suppressive myeloid populations in NSCLC 14 10 3

A SNAI2-PEAK1 stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting a cytokine expression profile that converges on PI3K/Akt signaling 14 3

TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway 98 14 3

Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling 108 14 3

Plasticity as an Underlying Mechanism of Tumor Heterogeneity in Breast Cancer 152 14 9

Cyclin G2 inhibits oral squamous cell carcinoma growth and metastasis by binding to insulin-like growth factor binding protein 3 and regulating the FAK-SRC-STAT signaling pathway 108 14 10 3

Loss of CPAP expression promotes sustained EGFR signaling and Epithelial-Mesenchymal Transition in oral cancer cells 98 14 3

ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to PARP inhibition in lung cancer 142 14 9 3

The pleiotropic effects of the MNK1/2-eIF4E axis support immune suppression and metastasis in a model of postpartum breast cancer. 14 10 3

The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer 14 10 3

PARP inhibition in Ewing sarcoma: impact of germline DNA damage repair defects and activation of immunoregulatory pathways 138 126 14 10 3

Sustained Androgen Receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis 108 14 10 3

Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy 14 10 9

Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment 173 126 14 10 3

Single cell analysis of colorectal cancer identifies mitogen-activated protein kinase as a key driver of tumor cell plasticity 152 148 142 14 9 3

Oncogenic GLI1 and STAT1/3 activation drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer cells 108 14 10 3

HDAC3 regulates senescence and lineage-specific transcriptional programs in non-small cell lung cancer 142 108 14 3

A novel mechanism of natural killer cell response to anti-CTLA-4 therapy identified by integrative analysis of mouse and human tumors 14 10 9 3

AMPK-Fyn signaling promotes Notch1 stability to potentiate hypoxia-induced breast cancer stemness and drug resistance 108 102 14 3

A 'one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer 152 126 14 10 3

A non-canonical EZH2 function sensitizes solid tumors to genotoxic stress 142 108 14 3

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers 138 126 14 10 3

Multi-organ signaling mobilizes tumor-associated erythroid cells expressing immune checkpoint molecules 14 10 3

Stromal Amyloid β drives Neutrophil extracellular trap formation to augment tumour growth 14 10 3

Transcriptional subtype-specific microenvironmental crosstalk and tumor cell plasticity in metastatic pancreatic cancer 152 14 9 3

Cyclic pentapeptide cRGDfK enhances the inhibitory effect of sunitinib on TGF-β1-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells 98 14 10 3

SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors 126 14 10 3

Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer 126 14 10 3

Induction of intracellular wild-type p53 amyloids leading to cellular transformation and tumor formation in mice 142 108 14 3

Taxane induces attenuation of the CXCR2/BCL-2 axis and sensitize prostate cancer to platinum-based treatments 126 14 10 3

Persistent cell proliferation signals correlates with increased glycolysis in tumor hypoxia microenvironment across cancer types 186 9

Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer 108 14 3

Frizzled-7 Identifies Platinum Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis 98 14 10 3

YAP and β-catenin co-operate to drive oncogenesis in basal breast cancer 108 14 3

Machine learning-based investigation of the cancer protein secretory pathway 112 14 9 4

Comparative study of transcriptomics-based scoring metrics for the epithelial-hybrid-mesenchymal spectrum 98 14 9 4

Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome 126 14 10

Thrombospondin-4 mediates hyperglycemia- and TGF-beta-induced inflammation in breast cancer 14 10 3

Role of neutrophil extracellular traps in regulation of lung cancer invasion and metastasis: Structural Insights from a Computational Model 14 10 3

Response to CAR T cell therapy can be explained by ecological cell dynamics and stochastic extinction events 14 10

A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors 126 14 10 3

Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling 108 14 10 3

Multiplex-inhibitor bead mass spectrometry reveals differential kinome signatures in newly diagnosed and recurrent glioblastoma 152 14 9 3

Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies 126 14 10 3

Expression of Tim-3 drives naive Treg to an effector-like state with enhanced suppressive activity 88 27 14 10 3

Postpartum breast cancer progression is driven by semaphorin 7a mediated invasion and survival 14 10 3

Inducible transgene expression in PDX models in vivo identifies KLF4 as therapeutic target for B-ALL 152 126 14 10 3

USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer 108 14 3

AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells 126 14 10 3

Metastatic signaling of hypoxia-related genes across TCGA Pan-Cancer types 186 14 9 3

Loss of Caspase-8 function in combination with SMAC mimetic treatment sensitizes Head and Neck Squamous Carcinoma to radiation through induction of necroptosis 126 108 14 10 3

Beta 1 Integrin Signaling Mediates Pancreatic Ductal Adenocarcinoma Resistance to MEK Inhibition 126 108 14 10 3

Analysis of single-cell RNA-seq data from ovarian cancer samples before and after chemotherapy links stress-related transcriptional profile withchemotherapy resistance 14 9

Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors 138 126 14 10 3

Splice-switching of the insulin receptor in rhabdomyosarcoma: Rescuing the IR-B isoform for better treatment options. 108 14 3

Gamma secretase inhibitors inhibit ovarian cancer development and enhance olaparib's anti-ovarian cancer activity and its mechanism 126 108 14 10 3

The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer 108 14 10 3

Characterizing the tumor microenvironment of metastatic ovarian cancer by single cell transcriptomics 148 14 9 3

ADAR1 editing dependency in triple-negative breast cancer 108 14 3

Iron and lipocalin-2 modulate cellular responses in the tumor micro-environment of pancreatic ductal adenocarcinoma 98 14 10 3

The landscape of metabolic pathway dependencies in cancer cell lines 186 9 3

Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo 142 14 10 3

Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach 126 14 10 3

Single-cell RNA-sequencing of peripheral neuroblastic tumors reveals an aggressive transitional cell state at the junction of an adrenergic-mesenchymal transdifferentiation trajectory 152 14 9 3

What is the storage effect, why should it occur in cancers, and how can it inform cancer therapy? 99 14 5

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity In Cancer 197 27 14 10 3

RRM2B is frequently amplified across multiple tumor types: non-oncogenic addiction and therapeutic opportunities 142 14 9 3

An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma 108 14 3

Systems biomedicine of primary and metastatic colorectal cancer reveals potential therapeutic targets 98 14 9 3